• Publication of an article on Estelle® endocrine and metabolic parameters in prestigious Contraception Journal
• Article concludes on limited impact of Estelle® compared to Ethinylestradiol-based combined oral contraceptives
• Estelle® filing on going in the U.S., Europe and Canada, with expected marketing authorization in H12021

Liege, Belgium, 9 February 2021- 7:30 CET - Mithra (Euronext Brussels: MITRA), a company dedicated to Women's Health, today announces the publication of a scientific paper entitled 'Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone' in Contraception Journal, one of the most prestigious peer-reviewed journals in the field. A link to this publication can be accessed here.

Attachments

  • Original document
  • Permalink

Disclaimer

Mithra Pharmaceuticals SA published this content on 09 February 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 February 2021 06:36:06 UTC.